The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kartos Therapeutics
Leadership - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
Travel, Accommodations, Expenses - Kartos Therapeutics
An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms.
 
Raajit Rampal
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene/Bristol-Myers Squibb; Constellation Pharmaceuticals; CTI; Disc Medicine; Galecto; Incyte; Jazz Pharmaceuticals; Novartis; PharmaEssentia; Promedior; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon
Research Funding - Constellation Pharmaceuticals; Incyte; Stemline Therapeutics; Zentalis
 
Sundra Ramanathan
No Relationships to Disclose
 
Cristina Papayannidis
Honoraria - Abbvie; Amgen; Astellas Pharma; Novartis; Pfizer
 
Nikolas von Bubnoff
Honoraria - Forum für Medizinische Fortbildung; Takeda
Consulting or Advisory Role - Novartis (Inst)
 
Maria del Mar Tormo Díaz
Honoraria - Amgen; Celgene/Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Novartis; Pfizer
 
Maria Belen Vidriales
Consulting or Advisory Role - Astellas Pharma; Jazz Pharmaceuticals
Speakers' Bureau - Astellas Pharma; Jazz Pharmaceuticals
 
Adolfo de la Fuente Burguera
Honoraria - Abbvie; Astellas Pharma; BSM; Incyte; Pfizer
Consulting or Advisory Role - BMS
Research Funding - Novartis (Inst)
 
Lucia Masarova
No Relationships to Disclose
 
Haifa Kathrin Al-Ali
Honoraria - Abbvie; BMSi; Incyte (Inst); Novartis; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; BMSi; Novartis
Research Funding - BMSi (Inst); Incyte (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - BMSi; Novartis; Novartis
 
David Lavie
Consulting or Advisory Role - Abbvie; BMS; Novartis; Roche; Takeda
 
Sandrine Niyongere
No Relationships to Disclose
 
Tiffanie Chan
Employment - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
 
Jesse S. McGreivy
No Relationships to Disclose
 
Wayne P. Rothbaum
Leadership - Iovance Biotherapeutics
Stock and Other Ownership Interests - Acerta Pharma/AstraZeneca (Inst); Kartos Therapeutics (Inst); Telios (Inst)
Patents, Royalties, Other Intellectual Property - Telios Pharma and Kartos Therapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Kartos Therapeutics
(OPTIONAL) Uncompensated Relationships - Kartos Therapeutics (Inst); Telios (Inst)
 
Alice S. Mims
Consulting or Advisory Role - Abbvie/Genentech; Agios; Astellas Pharma; Jazz Pharmaceuticals; Jazz Pharmaceuticals; PTC Therapeutics
 
Thomas Cluzeau
Honoraria - Alexion Pharmaceuticals; Amgen; Arog; Celgene/Bristol-Myers Squibb; Janssen; Kartos Therapeutics; Novartis; SERVIER; Syros Pharmaceuticals; Takeda
Consulting or Advisory Role - Abbvie; Agios; Celgene; Jazz Pharmaceuticals; Novartis; Roche
Speakers' Bureau - Amgen; Astellas Pharma; Celgene/Bristol-Myers Squibb; Kite/Gilead; Novartis
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Novartis; Pfizer